Biotechs targeting cancer, immunology likely to draw buyout bids

07/13/2011 | Reuters

Biotech companies that specialize in drugs for cancer, immune system diseases and brain conditions are likely to become attractive acquisition targets for Big Pharma, said investment bankers and other industry experts. Among such firms are Seattle Genetics, which has a drug candidate for two rare types of blood cancer, and Biogen Idec, which has multiple sclerosis drugs on the market.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Director of Litigation
Center for Science in the Public Interest
Washington, DC
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC